[Action of the anti-inflammatory agent Lonazolac on experimentally-induced acute inflammation of human skin].

Abstract

Using two experimental models of acute dermatitis in man, Lonazolac proved to possess dose-dependent anti-inflammatory effects. No untoward side effects were seen even at the higher doses of the drug. The results are consistent with animal studies: In its effect on the acute experimental dermatitis, Lonazolac resembles indomethacin more closely than oxyphenbutazone. It is superior to the comparable anti-inflammatory drugs in its effect on the inflammatory erythema of the skin; in its effect on the inflammatory edema of the skin, it stands between oxyphenbutazone and indomethacin.

• Authors: J Dethlefs
• Journal: Zeitschrift fur Rheumatologie (Z Rheumatol) 1978 Jul-Aug Vol. 37 Issue 7-8 Pg. 254-9 ISSN: 0340-1855 [Print] Germany
• Vernacular Title: Die Wirkung des Antiphlogistikum Lonazolac auf experimentell erzeugte akute Enlzündungen an der menschlichen Haut.
• PMID: 358658 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Acetates
• Anti-Inflammatory Agents
• Pyrazoles
• lonazolac
• Oxyphenbutazone
• Indomethacin

Topics

• Acetates (therapeutic use)
• Acute Disease
• Adolescent
• Adult
• Aged
• Anti-Inflammatory Agents (therapeutic use)
• Clinical Trials as Topic
• Dermatitis (drug therapy)
• Edema (drug therapy)
• Erythema (drug therapy)
• Female
• Humans
• Indomethacin (therapeutic use)
• Male
• Middle Aged
• Oxyphenbutazone (therapeutic use)
• Pyrazoles (therapeutic use)